Pacific Edge Triage Plus price set to boost economics

Pacific Edge (NZX:PEB) anticipates improved financial performance following the U.S. Centers for Medicare & Medicaid Services' (CMS) draft pricing for its Cxbladder Triage Plus test. The proposed price of US$1,018.44 is a substantial increase over the current US$760 price for existing tests, promising improved margins and profitability. The final price is subject to public comments, with CMS expected to make the finalized price effective January 1, 2026. The new pricing will apply to Medicare and Medicare Advantage patients, although private health insurers make separate coverage and pricing decisions. Pacific Edge plans to submit a reconsideration request for coverage, which is expected to positively impact the approximately 81% of the company's total US laboratory throughput represented by hematuria evaluation tests.